logo
Book a meeting
Genocea

Genocea

Biotechnology, 100 Acorn Park Drive, Cambridge, , 2140, Massachusetts, United States, 51-200 Employees

genocea.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is GENOCEA

Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Its proprietary ATLAS™ platform can comprehensively pro...

Read More

lock icon Get Full Access
map
  • 100 Acorn Park Drive, Cambridge, Massachusetts, 2140, United States Headquarters: 100 Acorn Park Drive, Cambridge, Massachusetts, 2140, United States
  • 2006 Date Founded: 2006
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $50 Million to $100 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 325414 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from GENOCEA

Genocea Org Chart and Mapping

Employees
Xun Li

Xun Li

Research Assistant

Alexander Lee

Alexander Lee

Senior Operations Manager - Clinical Laboratory Research

Kaitlyn Tursi

Kaitlyn Tursi

Accounting Specialist

Jazmyn Francis

Jazmyn Francis

Summer Intern

See Full Org Chart arrow
email-formate-icon
View Email Formats for Genocea
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding Genocea

Answer: Genocea's headquarters are located at 100 Acorn Park Drive, Cambridge, , 2140, Massachusetts, United States

Answer: Genocea's phone number is 61********

Answer: Genocea's official website is https://genocea.com

Answer: Genocea's revenue is $50 Million to $100 Million

Answer: Genocea's SIC: 2836

Answer: Genocea's NAICS: 325414

Answer: Genocea has 51-200 employees

Answer: Genocea is in Biotechnology

Answer: Genocea contact info: Phone number: 61******** Website: https://genocea.com

Answer: Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Its proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, InhibigensTM, that drive pro-tumor immune responses. Genocea is conducting a Phase 1/2a clinical trial for GEN-011, an adoptive T cell therapy comprised of neoantigen-targeted peripheral cells. Also, Genocea continues to monitor patients in its Phase 1/2a GEN-009 neoantigen vaccine clinical trial. In addition to the two clinical programs, Genocea is conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access